Hildebrandt MA - Search Results

1

Pu X, Hildebrandt MA, Lu C, Roth JA, Stewart DJ, Zhao Y, Heist RS, Ye Y, Chang DW, Su L, Minna JD, Lippman SM, Spitz MR, Christiani DC, Wu X. Pu X, et al. Among authors: hildebrandt ma. Clin Pharmacol Ther. 2014 Sep;96(3):360-369. doi: 10.1038/clpt.2014.89. Epub 2014 Apr 22. Clin Pharmacol Ther. 2014. PMID: 24755914 Free PMC article.

2

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.

Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Hildebrandt MA, et al. J Clin Oncol. 2009 Feb 20;27(6):857-71. doi: 10.1200/JCO.2008.17.6297. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164214 Free PMC article.

3

Pharmacogenomics of platinum-based chemotherapy in NSCLC.

Hildebrandt MA, Gu J, Wu X. Hildebrandt MA, et al. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):745-55. doi: 10.1517/17425250902973711. Expert Opin Drug Metab Toxicol. 2009. PMID: 19442035 Free PMC article. Review.

4

Genetic variation in MicroRNA genes and risk of oral premalignant lesions.

Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, Lee JJ, Wu X. Clague J, et al. Among authors: hildebrandt ma. Mol Carcinog. 2010 Feb;49(2):183-9. doi: 10.1002/mc.20588. Mol Carcinog. 2010. PMID: 19851984 Free PMC article.

5

Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.

Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu X. Chen M, et al. Among authors: hildebrandt ma. Carcinogenesis. 2009 Dec;30(12):2047-52. doi: 10.1093/carcin/bgp258. Carcinogenesis. 2009. PMID: 19875696 Free PMC article.

6

Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications.

Wu X, Hildebrandt MA, Chang DW. Wu X, et al. Among authors: hildebrandt ma. Cancer Metastasis Rev. 2009 Dec;28(3-4):269-80. doi: 10.1007/s10555-009-9190-y. Cancer Metastasis Rev. 2009. PMID: 20016998 Review.

7

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.

Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X. Pu X, et al. Among authors: hildebrandt ma. Lung Cancer. 2011 Jan;71(1):82-8. doi: 10.1016/j.lungcan.2010.04.008. Epub 2010 May 5. Lung Cancer. 2011. PMID: 20447721 Free PMC article.

8

Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Chen M, et al. Among authors: hildebrandt ma. Carcinogenesis. 2010 Aug;31(8):1387-91. doi: 10.1093/carcin/bgq110. Epub 2010 Jun 7. Carcinogenesis. 2010. PMID: 20530239 Free PMC article.

9

Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma.

Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X. Hildebrandt MA, et al. Oncogene. 2010 Oct 21;29(42):5724-8. doi: 10.1038/onc.2010.305. Epub 2010 Aug 2. Oncogene. 2010. PMID: 20676129

10

Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.

Hildebrandt MA, Komaki R, Liao Z, Gu J, Chang JY, Ye Y, Lu C, Stewart DJ, Minna JD, Roth JA, Lippman SM, Cox JD, Hong WK, Spitz MR, Wu X. Hildebrandt MA, et al. PLoS One. 2010 Aug 25;5(8):e12402. doi: 10.1371/journal.pone.0012402. PLoS One. 2010. PMID: 20811626 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

159 results

Search Page